Lipofermata

Cat. No.:	HY-116788				
CAS No.:	297180-15-5				
Molecular Formula:	C ₁₅ H ₁₀ BrN ₃ OS				
Molecular Weight:	360.23				
Target:	Bacterial				
Pathway:	Anti-infection				
Storage:	Powder	-20°C	3 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (277.60 mM; Need ultrasonic)						
Preparing Stock Solution		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.7760 mL	13.8800 mL	27.7600 mL		
		5 mM	0.5552 mL	2.7760 mL	5.5520 mL		
		10 mM	0.2776 mL	1.3880 mL	2.7760 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.77 mM); Clear solution						
	2. Add each solvent Solubility: ≥ 2.08 r	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.77 mM); Clear solution					

Diological					
Description	Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC ₅₀ of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM ^{[1][2][3]} .				
In Vitro	Lipofermata inhibits C1-BODIPY-C12 transport into C2C12, INS-1E, Caco-2 and HepG2 cells at comparable levels yielding sigmoidal dose-response curves with IC ₅₀ s in the low micromolar range (IC ₅₀ =2.74-39.34 μM) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

CUSTOMER VALIDATION

HN

Br

റ



• JHEP Rep. 2023 Aug 21.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Falconer SB, et al. Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. ACS Infect Dis. 2015;1(11):533-543.

[2]. Sandoval A, et al. Identification and characterization of small compound inhibitors of human FATP2 [published correction appears in Biochem Pharmacol. 2012 Aug 15;84(4):580]. Biochem Pharmacol. 2010;79(7):990-999.

[3]. Ahowesso C, Black PN, Saini N, et al. Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochem Pharmacol. 2015;98(1):167-181.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA